Defending the 21st Century Cures Act

VideoEd Silverman, writing in the Boston Globe October 19th, pointed to lung cancer drug Iressa as a “cautionary tale” against using “surrogate endpoints” – signs that point to, but don’t guarantee, a given clinical outcome – for FDA drug approvals. He suggests that the 21st Century Cures Act, which encourages […]